Numerous randomized controlled trials (RCTs) have demonstrated the glycemic benefits of continuous glucose monitoring (CGM) in management of type 1 diabetes (T1D) and type 2 diabetes. Although RCTs remain the gold standard clinical study design, findings from these trials do not necessarily reflect the effectiveness of CGM or reveal the feasibility and wider applications for use in broader real-life settings. This review evaluates recent real-world evidence (RWE) demonstrating the value of CGM to improve clinical outcomes, such as avoidance of severe hypoglycemic and hyperglycemic crises, and improved measures of psychological health and quality of life. Additionally, this review considers recent RWE for the role of CGM to enhance health care resource utilization, including prediction of T1D and applications in gestational diabetes, chronic kidney disease, and monitoring during surgery.
|Journal||Diabetes Technology & Therapeutics|
|Early online date||24 Jun 2021|
|Publication status||Published - Sep 2021|
Bibliographical note© James R. Gavin, III and Clifford J. Bailey, 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Funding for the development of the manuscript was provided by Abbott Diabetes Care.
- Type 1 diabetes
- Type 2 diabetes